G9pharma co., LTD announced a private placement of round 17 unregistered nonguaranteed private convertible bonds for gross proceeds of KRW 1,500,000,000 on November 26, 2021. The transaction include participation from new investor Cypress Partners Co., Ltd. for all the securities issued. The bonds bear a fixed coupon rate of 0% and will mature on December 14, 2024, the interest rate to maturity 0%. The bonds are fully convertible into 207,641 common shares from December 14, 2022 to November 14, 2024 at a fixed conversion price of KRW 7,224 per share. The expected payment date for bonds is December 14, 2021. The share subscription date is on November 29, 2021. The transaction was approved by the board of directors of the company. The securities issued are subjected to one year hold period. On December 7, 2021, the company announced that the bonds are fully convertible into 307,377 common shares at a fixed conversion price of KRW 4,880 per share. The share subscription date is on December 9, 2021.